With the aim of generating effective antigen-specific CD8+ cytotoxic T lymphocyte (CTL) responses against prostate cancer, we designed two different SNA structures formulated with peptides derived from different prostate tumor-associated antigens and evaluated their efficacy as vaccines in tumor-free and prostate tumor settings, compared to those by an admix of linear CpG and peptide antigen. This evidence concerns the gene CD8A and prostate neoplasm.